Payment overview · 2025
General Payments
$30,167.16
120 reported records · 13 companies
Healthcare provider profile · identity verified
Kevin Manocha, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · RALEIGH, NC · NPI 1518304625
Verified facts
What the public records show
CMS Open Payments records show Kevin Manocha, MD received $30,167.16 in general payments during 2025 across 120 reported records.
BIOTRONIK INC. accounted for 65.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $19,852.28 | 65.8% | 35 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$4,824.61 | 16.0% | 31 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,796.46 | 9.3% | 19 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $1,445.84 | 4.8% | 9 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $277.29 | 0.9% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $206.62 | 0.7% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $206.39 | 0.7% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $178.51 | 0.6% | 2 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $130.23 | 0.4% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $99.48 | 0.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $61.44 | 0.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.74 | 0.2% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $40.27 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $21,809.41 | 25 |
| Food and Beverage | $6,957.75 | 94 |
| Consulting Fee | $1,400.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,917.42 | 6 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $1,409.35 | 8 | 2025 |
Source payment records
|
|||||
| Selectra Normalized: selectra |
Device | BIOTRONIK INC. | $951.97 | 8 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $732.30 | 5 | 2025 |
Source payment records
|
|||||
| EVERA MRI XT DR SURESCAN Normalized: evera mri xt dr surescan |
Device | Medtronic, Inc. | $612.98 | 7 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $303.51 | 4 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $303.34 | 2 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $204.69 | 3 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $166.88 | 5 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $164.03 | 2 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $147.50 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $140.60 | 4 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $134.20 | 1 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $130.23 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $123.54 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $122.64 | 3 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $121.75 | 1 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $110.41 | 2 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $109.30 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $108.95 | 3 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $99.48 | 1 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $99.48 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $99.48 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $98.89 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $97.44 | 2 | 2025 |
Source payment records
|
|||||
| PAMIRA Normalized: pamira |
Device | BIOTRONIK INC. | $84.22 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $72.42 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $61.44 | 6 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $47.74 | 1 | 2025 |
Source payment records
|
|||||
| DERMABOND Normalized: dermabond |
Device | Ethicon US, LLC | $40.27 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $40.27 | 1 | 2025 |
Source payment records
|
|||||
| MONOCRYL Normalized: monocryl |
Device | Ethicon US, LLC | $40.27 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $40.27 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $36.49 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $32.93 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $31.01 | 1 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $17.73 | 2 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $11.86 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $11.27 | 1 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $7.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 240 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 66 |
| Flecainide Acetate | Flecainide Acetate | 61 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 25 |
| Furosemide | Furosemide | 50 | 17 |
| Sotalol | Sotalol Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 28 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,167.16 · 120 records | BIOTRONIK INC. | AFFERA MAPPING SYSTEM, AMVIA EDGE, ANGIO-SEAL, ATRICLIP LAA EXCLUSION SYSTEM, AURORA EV-ICD MRI SURESCAN, AVEIR, AZURE XT DR MRI SURESCAN, Acticor 7 VR-T DX, BIOMONITOR, BodyGuardian, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, COBALT DR MRI SURESCAN, DERMABOND, EMBLEM MRI S-ICD, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ETHICON, EVERA MRI XT DR SURESCAN, Extended Holter, FARAPULSE, GLIDEWIRE, General - Therapies, INGEVITY+, JOT DX, LM Undivided, LifeVest, METACROSS OTW, MONOCRYL, PAMIRA, QDOT MICRO, Rhythmia Mapping System, SELECTSECURE, STRATAFIX, SYNERGY ABLATION SYSTEM, Selectra, Solia, VYNDAQEL, WATCHMAN FLX, remede System | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error